BACKGROUND: In patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), studies have suggested that reduced left ventricular (LV) ejection fraction (LVEF) and low aortic valve gradient (AVG) are associated with worse long-term outcomes. Because these conditions commonly coexist, the extent to which they are independently associated with outcomes after TAVR is unknown. OBJECTIVES: The purpose of this study was to evaluate the impact of LVEF and AVG on clinical outcomes after TAVR and to determine whether the effect of AVG on outcomes is modified by LVEF. METHODS: Using data from 11,292 patients who underwent TAVR as part of the Transcatheter Valve Therapies Registry, we examined rates of 1-year mortality and recurrent heart failure in patients with varying levels of LV dysfunction (LVEF <30% vs. 30% to 50% vs. >50%) and AVG (<40 mm Hg vs. ≥40 mm Hg). Multivariable models were used to estimate the independent effect of AVG and LVEF on outcomes. RESULTS: During the first year of follow-up after TAVR, patients with LV dysfunction and low AVG had higher rates of death and recurrent heart failure. After adjustment for other clinical factors, only low AVG was associated with higher mortality (hazard ratio: 1.21; 95% confidence interval: 1.11 to 1.32; p < 0.001) and higher rates of heart failure (hazard ratio: 1.52; 95% confidence interval: 1.36 to 1.69; p <0.001), whereas the effect of LVEF was no longer significant. There was no evidence of effect modification between AVG and LVEF with respect to either endpoint. CONCLUSIONS: In this series of real-world patients undergoing TAVR, low AVG, but not LV dysfunction, was associated with higher rates of mortality and recurrent heart failure. Although these findings suggest that AVG should be considered when evaluating the risks and benefits of TAVR for individual patients, neither severe LV dysfunction nor low AVG alone or in combination provide sufficient prognostic discrimination to preclude treatment with TAVR.
BACKGROUND: In patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), studies have suggested that reduced left ventricular (LV) ejection fraction (LVEF) and low aortic valve gradient (AVG) are associated with worse long-term outcomes. Because these conditions commonly coexist, the extent to which they are independently associated with outcomes after TAVR is unknown. OBJECTIVES: The purpose of this study was to evaluate the impact of LVEF and AVG on clinical outcomes after TAVR and to determine whether the effect of AVG on outcomes is modified by LVEF. METHODS: Using data from 11,292 patients who underwent TAVR as part of the Transcatheter Valve Therapies Registry, we examined rates of 1-year mortality and recurrent heart failure in patients with varying levels of LV dysfunction (LVEF <30% vs. 30% to 50% vs. >50%) and AVG (<40 mm Hg vs. ≥40 mm Hg). Multivariable models were used to estimate the independent effect of AVG and LVEF on outcomes. RESULTS: During the first year of follow-up after TAVR, patients with LV dysfunction and low AVG had higher rates of death and recurrent heart failure. After adjustment for other clinical factors, only low AVG was associated with higher mortality (hazard ratio: 1.21; 95% confidence interval: 1.11 to 1.32; p < 0.001) and higher rates of heart failure (hazard ratio: 1.52; 95% confidence interval: 1.36 to 1.69; p <0.001), whereas the effect of LVEF was no longer significant. There was no evidence of effect modification between AVG and LVEF with respect to either endpoint. CONCLUSIONS: In this series of real-world patients undergoing TAVR, low AVG, but not LV dysfunction, was associated with higher rates of mortality and recurrent heart failure. Although these findings suggest that AVG should be considered when evaluating the risks and benefits of TAVR for individual patients, neither severe LV dysfunction nor low AVG alone or in combination provide sufficient prognostic discrimination to preclude treatment with TAVR.
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Patrizio Lancellotti; Erwan Donal; Julien Magne; Kim O'Connor; Marie L Moonen; Bernard Cosyns; Luc A Pierard Journal: Eur J Echocardiogr Date: 2010-03-04
Authors: Alexander Lauten; Hans R Figulla; Helge Möllmann; David Holzhey; Joachim Kötting; Andreas Beckmann; Christof Veit; Jochen Cremer; Karl-Heinz Kuck; Rüdiger Lange; Ralf Zahn; Stefan Sack; Gerhard Schuler; Thomas Walther; Friedhelm Beyersdorf; Michael Böhm; Gerd Heusch; Thomas Meinertz; Till Neumann; Armin Welz; Friedrich W Mohr; Christian W Hamm Journal: EuroIntervention Date: 2014-11 Impact factor: 6.534
Authors: Michael E Halkos; Edward P Chen; Eric L Sarin; Patrick Kilgo; Vinod H Thourani; Omar M Lattouf; J David Vega; Cullen D Morris; Thomas Vassiliades; William A Cooper; Robert A Guyton; John D Puskas Journal: Ann Thorac Surg Date: 2009-09 Impact factor: 4.330
Authors: Howard C Herrmann; Philippe Pibarot; Irene Hueter; Zachary M Gertz; William J Stewart; Samir Kapadia; E Murat Tuzcu; Vasilis Babaliaros; Vinod Thourani; Wilson Y Szeto; Joseph E Bavaria; Susheel Kodali; Rebecca T Hahn; Mathew Williams; D Craig Miller; Pamela S Douglas; Martin B Leon Journal: Circulation Date: 2013-05-09 Impact factor: 29.690
Authors: Sammy Elmariah; Igor F Palacios; Thomas McAndrew; Irene Hueter; Ignacio Inglessis; Joshua N Baker; Susheel Kodali; Martin B Leon; Lars Svensson; Philippe Pibarot; Pamela S Douglas; William F Fearon; Ajay J Kirtane; Hersh S Maniar; Jonathan J Passeri Journal: Circ Cardiovasc Interv Date: 2013-11-12 Impact factor: 6.546
Authors: Frédéric Maes; Stamatios Lerakis; Henrique Barbosa Ribeiro; Martine Gilard; João L Cavalcante; Raj Makkar; Howard C Herrmann; Stephan Windecker; Maurice Enriquez-Sarano; Asim N Cheema; Luis Nombela-Franco; Ignacio Amat-Santos; Antonio J Muñoz-García; Bruno Garcia Del Blanco; Alan Zajarias; John C Lisko; Salim Hayek; Vasilis Babaliaros; Florent Le Ven; Thomas G Gleason; Tarun Chakravarty; Wilson Szeto; Marie-Annick Clavel; Alberto de Agustin; Vicenç Serra; John T Schindler; Abdellaziz Dahou; Mohammed Salah-Annabi; Emilie Pelletier-Beaumont; Melanie Côté; Rishi Puri; Philippe Pibarot; Josep Rodés-Cabau Journal: JAMA Cardiol Date: 2019-01-01 Impact factor: 14.676
Authors: Mohamad Alkhouli; Ahmed Al Mustafa; Zakeih Chaker; Fahad Alqahtani; Sami Aljohani; David R Holmes Journal: J Card Surg Date: 2017-03-07 Impact factor: 1.620
Authors: Angela Lowenstern; Steven J Lippmann; J Matthew Brennan; Tracy Y Wang; Lesley H Curtis; Ted Feldman; Donald D Glower; Bradley G Hammill; Sreekanth Vemulapalli Journal: Circ Cardiovasc Interv Date: 2019-05 Impact factor: 6.546
Authors: Edward T Carreras; Tsuyoshi Kaneko; Fernando Ramirez-Del Val; Marc P Pelletier; Piotr S Sobieszczyk; Deepak L Bhatt; Pinak B Shah Journal: Catheter Cardiovasc Interv Date: 2017-10-08 Impact factor: 2.692
Authors: Norman Mangner; Georg Stachel; Felix Woitek; Stephan Haussig; Florian Schlotter; Robert Höllriegel; Jennifer Adam; Anna Lindner; Friedrich W Mohr; Gerhard Schuler; Philipp Kiefer; Sergey Leontyev; Michael A Borger; Holger Thiele; David Holzhey; Axel Linke Journal: J Am Heart Assoc Date: 2018-04-13 Impact factor: 5.501
Authors: Francisco J Romeo; Ignacio M Seropian; Sameer Arora; John P Vavalle; Mariano Falconi; Pablo Oberti; Vadim Kotowicz; Carla R Agatiello; Daniel H Berrocal Journal: Cardiovasc Diagn Ther Date: 2020-02